Photo
Business Update

Reuters business newsletter, your daily business coverage.

Subscribe

Bayer says structure and politics deter bidders

Wed Nov 19, 2008 12:26pm EST

Reporter's Notebook

[-] Text [+]

NEW YORK (Reuters) - Bayer AG (BAYG.DE: Quote, Profile, Research, Stock Buzz) is not an obvious candidate to be bought by a larger drug maker, given its complex structure and potential political obstacles facing a foreign buyer, the group's head of health care said on Wednesday.

There has been persistent speculation this year that Pfizer Inc (PFE.N: Quote, Profile, Research, Stock Buzz) or Novartis AG (NOVN.VX: Quote, Profile, Research, Stock Buzz) might try to snap up the German pharmaceuticals-and-chemicals conglomerate, which has a market capitalization of around 30 billion euros ($38 billion).

But Arthur Higgins, chief executive of Bayer HealthCare, the company's most profitable division, poured cold water on the idea.

"We don't comment on rumors but these are not very well-founded," he told the Reuters Health Summit in New York.

"Don't get me wrong: they've all looked at us, because you'd be crazy not to -- if you didn't have those impediments, we'd probably be top of the list."

Bayer boasts a healthy pipeline of new drugs and an attractive over-the-counter medicines business. But any acquisition by a pure pharmaceutical company would involve a tricky breakup of the group, since Bayer is also a global player in plastics and in agrochemicals.

"There is a natural protection that comes from who we are. We're still a conglomerate. We're far too complex for those companies that you've just described to even begin to imagine how they would deal with such complexity," Higgins said.

There would also be major political repercussions from the takeover of what Higgins described as a "German heritage company," which could well lead to objections from the government and the country's labor unions.

Bayer became a major champion for the German pharmaceutical sector when it bought its smaller rival, Schering AG, in 2006.

Pfizer and Novartis have consistently declined to comment on the takeover rumors.

(Reporting by Ben Hirschler and Sam Cage; editing by Matthew Lewis)

 
 
 
Aerospace and Defense Dec 15 - 17, 2008 Aerospace/Defense
Investment Outlook Dec 08 - 11, 2008 Financial Services / Exchanges
Media Dec 01 - 4, 2008 Media/Tech/Telco
India Investment Nov 24 - 26, 2008 Country Summits
Health Nov 17 - 20, 2008 Health

What are Summits?

Reuters Summits are your direct link to top business leaders, investors and regulators. Our journalists interview heavyweights in a particular industry, spin out hard-hitting breaking news and sharp analysis that can often move markets. If you want to understand what the insiders are thinking, look for Reuters Summits.  Launch Full Video 

 

Stay connected. Get e-mailed alerts with schedules, speaker lists, and headlines from upcoming and live Industry Summits.